AGP Executive Report
Last update: 12 hours agoPancreatic Cancer: The European Commission has authorised Rasonque for adults with metastatic pancreatic cancer after at least one prior systemic treatment. The approval covers Liechtenstein, but patient access will depend on local pricing and reimbursement. Ovarian Cancer: Sepalna has won European approval as maintenance therapy after first-line chemotherapy for certain patients with advanced ovarian, fallopian tube or peritoneal cancer; Liechtenstein is among the markets covered by its regional rights. Short Bowel Syndrome: The EU has approved Zeydovio, a twice-weekly treatment for adults with short bowel syndrome, marking the first major European treatment advance for the condition in more than a decade. Respiratory Health: EU advisers recommend expanding Merck’s RSV prevention treatment to protect some high-risk children through a second season. The European Commission is expected to decide within two months; the proposed coverage includes Liechtenstein.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.